However, two HER4 mutations (L1227M and I1226T) were present in C-33A, a cervical cancer cell line without amplification or mutations in EGFR, HER2, or HER3,38 that was potently inhibited by neratinib (Supplementary Table S1). This evidence concerns the gene ERBB4 and cervical carcinoma.